PE20230491A1 - Compuestos de imidazopiridazina con actividad como inhibidores de alk2 - Google Patents

Compuestos de imidazopiridazina con actividad como inhibidores de alk2

Info

Publication number
PE20230491A1
PE20230491A1 PE2022002872A PE2022002872A PE20230491A1 PE 20230491 A1 PE20230491 A1 PE 20230491A1 PE 2022002872 A PE2022002872 A PE 2022002872A PE 2022002872 A PE2022002872 A PE 2022002872A PE 20230491 A1 PE20230491 A1 PE 20230491A1
Authority
PE
Peru
Prior art keywords
azabicyclo
activity
imidazol
ethyl
alk2
Prior art date
Application number
PE2022002872A
Other languages
English (en)
Inventor
Wenqing Yao
Yu Bai
Liangxing Wu
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of PE20230491A1 publication Critical patent/PE20230491A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Dental Preparations (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Esta referido a derivados de imidazopiridazina de Formula I, en donde: R1 es 1-etil-1H-imidazol-4-ilo o 4-metil-2H-1,2,3-triazol-2-ilo; y R2 es (1R,5S)-3-(tetrahidro-2H-piran-4-il)-3-azabiciclo[3.1.0]hexan-1-ilo o 2-metil2-azabiciclo[2.2.2]octano. Entre los compuestos preferidos tenemos : 2-(1-etil-1H-imidazol-4-il)-5-(6-metil-7-(4-((1R,5S)-3-(tetrahidro-2H-piran-4-il)-3- azabiciclo[3.1.0]hexan-1-il)fenil)imidazo[1,2-b]piridazin-3-il)-1,8-naftiridina; 2-(4-(3-(7-(1-etil-1H-imidazol-4-il)-1,8-naftiridin-4-il)-6-metilimidazo[1,2-b]piridazin-7-il)bencil)-2- azabiciclo[2.2.2]octano; entre otros. Los compuestos modulan la actividad de la quinasa-2 similar al receptor de activina (ALK2) y son utiles en el tratamiento de diversas enfermedades, incluido el cancer.
PE2022002872A 2020-06-12 2021-06-10 Compuestos de imidazopiridazina con actividad como inhibidores de alk2 PE20230491A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063038410P 2020-06-12 2020-06-12
PCT/US2021/036839 WO2021252781A1 (en) 2020-06-12 2021-06-10 Imidazopyridazine compounds with activity as alk2 inhibitors

Publications (1)

Publication Number Publication Date
PE20230491A1 true PE20230491A1 (es) 2023-03-23

Family

ID=76971994

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022002872A PE20230491A1 (es) 2020-06-12 2021-06-10 Compuestos de imidazopiridazina con actividad como inhibidores de alk2

Country Status (17)

Country Link
US (2) US11840546B2 (es)
EP (1) EP4165051A1 (es)
JP (1) JP2023530088A (es)
KR (1) KR20230025434A (es)
CN (1) CN115956081A (es)
AR (1) AR122587A1 (es)
AU (1) AU2021288107A1 (es)
BR (1) BR112022025191A2 (es)
CA (1) CA3184811A1 (es)
CL (1) CL2022003453A1 (es)
CO (1) CO2022017969A2 (es)
EC (1) ECSP22093652A (es)
IL (1) IL298248A (es)
MX (1) MX2022015493A (es)
PE (1) PE20230491A1 (es)
TW (1) TW202214660A (es)
WO (1) WO2021252781A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3898627A1 (en) 2018-12-20 2021-10-27 Incyte Corporation Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03000051A (es) 2000-06-28 2003-08-19 Smithkline Beecham Plc Procedimiento de molido en humedo.
ATE522249T1 (de) * 2007-07-26 2011-09-15 Novartis Ag Organische verbindungen
US8367662B2 (en) 2007-10-17 2013-02-05 Novartis Ag Organic compounds
EP2598505B1 (en) 2010-07-28 2015-03-18 Bayer Intellectual Property GmbH Substituted imidazo[1,2-b]pyridazines
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
JP5976788B2 (ja) 2011-05-06 2016-08-24 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾピリジンおよびイミダゾピリダジンならびにそれらの使用
US9682983B2 (en) 2013-03-14 2017-06-20 The Brigham And Women's Hospital, Inc. BMP inhibitors and methods of use thereof
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
PL3377488T3 (pl) 2015-11-19 2022-12-19 Incyte Corporation Związki heterocykliczne jako immunomodulatory
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
ES2844374T3 (es) 2015-12-22 2021-07-22 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
TW201808950A (zh) 2016-05-06 2018-03-16 英塞特公司 作為免疫調節劑之雜環化合物
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
IL263825B (en) 2016-06-20 2022-08-01 Incyte Corp Heterocyclic compounds as immunomodulators
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
EP3512834A4 (en) 2016-09-14 2020-05-06 Vanderbilt University INHIBIT OF BMP SIGNALING, CONNECTIONS, COMPOSITIONS AND USES THEREOF
CA3036101A1 (en) 2016-09-15 2018-03-22 Armstrong World Industries, Inc. Ceiling system with air movement
ES2918974T3 (es) 2016-12-22 2022-07-21 Incyte Corp Compuestos heteroaromaticos biciclicos como inmunomoduladores
CA3047986A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Benzooxazole derivatives as immunomodulators
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
PE20200005A1 (es) 2016-12-22 2020-01-06 Incyte Corp Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de internalizacion pd-l1
MA47120A (fr) 2016-12-22 2021-04-28 Incyte Corp Dérivés pyridine utilisés en tant qu'immunomodulateurs
US20180177784A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018136634A1 (en) * 2017-01-18 2018-07-26 Vanderbilt University Fused heterocyclic compounds as selective bmp inhibitors
WO2018165569A1 (en) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Therapeutic compounds and methods
EP3898627A1 (en) * 2018-12-20 2021-10-27 Incyte Corporation Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2

Also Published As

Publication number Publication date
US20240083918A1 (en) 2024-03-14
CN115956081A (zh) 2023-04-11
US20210388003A1 (en) 2021-12-16
WO2021252781A1 (en) 2021-12-16
JP2023530088A (ja) 2023-07-13
ECSP22093652A (es) 2023-02-28
CL2022003453A1 (es) 2023-05-26
MX2022015493A (es) 2023-03-21
CA3184811A1 (en) 2021-12-16
KR20230025434A (ko) 2023-02-21
AR122587A1 (es) 2022-09-21
IL298248A (en) 2023-01-01
TW202214660A (zh) 2022-04-16
CO2022017969A2 (es) 2023-02-27
BR112022025191A2 (pt) 2023-03-07
EP4165051A1 (en) 2023-04-19
US11840546B2 (en) 2023-12-12
AU2021288107A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
US11566003B2 (en) Isoquinolines as inhibitors of HPK1
US7608622B2 (en) Imidazo[4,5-b]pyrazinone inhibitors of protein kinases
US10227357B2 (en) Compounds and methods for kinase modulation, and indications therefor
PE20110828A1 (es) Compuestos de pirazolopirimidina como inhibidores de jak
AU2014253348B2 (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
PE20121511A1 (es) Novedosos derivados biciclicos de triazol sustituidos como moduladores de gamma secretasa
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
RU2012145237A (ru) Производные арилэтинила
PE20230491A1 (es) Compuestos de imidazopiridazina con actividad como inhibidores de alk2
JP2021506889A5 (es)
MX2014009089A (es) Compuestos de imidazopirrolidinona.
PE20120304A1 (es) Derivados de 1,3-tiazolidina-2,4-diona con actividad sobre quinasas pim-1 y/o pim-2 y/o pim-3
CL2010001486A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak; composicion farmaceutica; kit farmaceutico; su uso en el tratamiento de enfermedades tales como cancer, diabetes, enfermedad de alzheimer, enfermedad hepatica, trastornos del snc, entre otras.
PE20091724A1 (es) Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7
CL2009000724A1 (es) Compuestos derivados de 1,2,3,4-tetrahidro-pirido[3,4-b]indol, moduladores del receptor de histamina, serotonina y dopamina; composicion farmaceutica; kit farmaceutico; y uso para tratar un trastorno cognitivo, psicotico, mediado por neurotransmisores y/o neurologico.
WO2008070150A1 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
AR114443A1 (es) Oxadiazoles fungicidas y un proceso para su preparación
PE20220578A1 (es) Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades
PE20040082A1 (es) Derivados del tropano como moduladores de los receptores ccr5
EP2244721A2 (en) Sulfone substituted 2,3-dihydroimidazo ý1,2-c¨quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
TW202014417A (zh) 嘧啶化合物及包括其之供預防或治療癌症的藥學組成物
PE20041006A1 (es) Compuestos de (1h-indazol-6-ilamino) como inhibidores de proteinquinasa
AR048001A1 (es) Hidroxi - 6 - fenilantridinas que contienen tio con actividad inhibitoria de pde4 y composiciones farmaceuticas que las contienen para el tratamiento de trastornos respiratorios.
PE20091349A1 (es) Compuestos derivados de espiro 1,3,4-tiadiazol como inhibidores de la actividad quinesina ksp
PE20090944A1 (es) PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT